Initial U.S. Approval: 2014
Trumenba is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B… approved for use in individuals 10 through 25 years of age.
Serious Adverse Events
SAEs were reported by… 1.6% subjects… who received at least one dose of Trumenba…
Non-serious Adverse Events
AEs that occurred within 30 days of vaccination were reported in… 30.6% subjects who received at least one dose of Trumenba…
Postmarketing Experience
Hypersensitivity reactions, including anaphylactic reactions.
Syncope (fainting).
Polysorbate 80 (PS80) is added to the drug substances and is present in the final drug product.
Each 0.5 mL dose contains… 0.25 mg of Al3+ [aluminum] as AlPO4 [aluminum phosphate]…
Trumenba has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility in males.